<DOC>
	<DOCNO>NCT01568125</DOCNO>
	<brief_summary>It well know incretin , particular GLP-ï¼‘enhances satiety reduce energy intake control appetite dietary human ( Flint A , et al . Gutzwiller JP et al. ) . Recently , incretin-based therapy attract lot interest ( Hare KJ , Knop FK ) . However , clear incretin-based therapy affect energy content dietary intake patient type 2 diabetes mellitus ( T2DM ) . Previously , investigator report amount energy content dietary intake type 2 diabetic Japanese patient 10 year long time duration discovery use questionnaire ( Inoue K et al . ) patient impaired secretion active GLP-1 ( Kamoi et al ) . The investigator examine whether incretin-based therapy effect energy content dietary intake patient one year administration incretin-related drug use method previously ( Inoue K et al . ) .</brief_summary>
	<brief_title>Effect Incretin-related Drugs Dietary Intake Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>Japanese patient T2DM without incretinbased therapy , participate examine energy content intake use questionnaire report previously . Patients serious complication heart , liver kidney Pregnant possibly pregnant patient lactate patient Patients complicate malignant tumor present . Patients participate clinical study . Other , patient judge inappropriate subject study investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>